LifeCodexx, a subsidiary of GATC Biotech and a biotech company that focuses on the development of molecular diagnostics based on next generation sequencing technologies, has started operational research and development work on clinically validated diagnostic tests in the field of prenatal diagnostics.

LifeCodexx aims to establish ‘Next Generation Molecular Diagnostics’ in Europe. This will provide improved diagnostics for targeted, cost-efficient treatments. The test development currently being undertaken also receives public funding, including up to EUR300,000 from the ZIMSolo and KMU Innovative funding programs.

LifeCodexx is expected to utilize GATC Biotech’s sequencing laboratory, which is the European provider with a total capacity of more than 2 terabases per year.

Peter Pohl, CEO of GATC Biotech and chairman of the board of LifeCodexx, said: “LifeCodexx AG has a revolutionary concept to carry out human genetic diagnostic tests based on state of the art sequencing technologies. This will drastically improve cost efficiency in diagnostics. LifeCodexx AG will be a trailblazer here”

Michael Lutz, new CEO of LifeCodexx, said: “Our test pipeline in prenatal diagnostics shows encouraging results which we will present in the coming months. I am delighted to be able to apply my experience to these innovative projects.”

GATC Biotech is Europe’s service provider of DNA sequencing and bioinformatics for industry and academic research. The company has been developing solutions for DNA sequence analysis for single samples up to whole genome, transcriptome and metagenome projects.